Serum Amyloid A as a prognostic marker for disease severity and mortality in COVID-19
- Conditions
- COVID-19
- Registration Number
- NL-OMON20323
- Lead Sponsor
- Board of Directors Franciscus Gasthuis & Vlietland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 350
Inclusion Criteria
18 jaar or older;
hospitalised for (suspicion of) COVID-19;
written informed consent for those subjects admitted to the non-ICU clinical COVID-19 ward.
Exclusion Criteria
Subjects undergoing experimental interventions will be excluded.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference in sensitivity of blood plasma SAA, CRP , ferritin and PCT levels on day 1, day 3, day 5 and day 7 of hospital stay in patients with severe versus non-severe COVID-19 disease course.
- Secondary Outcome Measures
Name Time Method •Specificity, positive and negative predictive values, positive and negative likelihood ratios SAA versus CRP, ferritin and PCT.<br>•Clinical course of COVID-19 including classification of COVID-19 severity according to the WHO criteria (Clinical management of COVID-19 (who.int)).<br>•Disease outcome at time of hospital discharge (or death).